Edition:
United States

Nabriva Therapeutics PLC (NBRV.OQ)

NBRV.OQ on NASDAQ Stock Exchange Global Select Market

3.46USD
20 Jul 2018
Change (% chg)

$0.04 (+1.17%)
Prev Close
$3.42
Open
$3.42
Day's High
$3.55
Day's Low
$3.40
Volume
28,158
Avg. Vol
80,625
52-wk High
$14.09
52-wk Low
$3.31

Select another date:

Mon, May 21 2018

Nabriva shares tumble as safety worries plague pneumonia drug

Nabriva Therapeutics Plc's antibiotic drug to treat a common form of pneumonia met the main goal of a key clinical trial, but concerns over its side effects sent the drug developer's shares down 13 percent on Monday.

UPDATE 3-Nabriva shares tumble as safety worries plague pneumonia drug

* Co to seek approval for drug in Q4 2018 (Adds analyst quote, updates stock price)

BRIEF-Nabriva Announces Positive Results For Pneumonia Treatment

* NABRIVA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF ORAL LEFAMULIN FOR THE TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA

Nabriva's pneumonia drug succeeds in late-stage study

May 21 Nabriva Therapeutics Plc said on Monday its drug to treat adults suffering from a type of pneumonia met the main goal of a late-stage study.

BRIEF-Nabriva Therapeutics Reports Q1 Loss Per Share $0.36

* NABRIVA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

BRIEF-Nabriva Therapeutics And Roivant Sciences Enter Into License Agreement

* NABRIVA THERAPEUTICS AND ROIVANT SCIENCES ENTER INTO LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE LEFAMULIN IN GREATER CHINA

BRIEF-Nabriva Appoints Jennifer Schranz As Chief Medical Officer

* NABRIVA THERAPEUTICS APPOINTS JENNIFER SCHRANZ, M.D., AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Nabriva Therapeutics PLC Files For Mixed Shelf Of Upto $225 Million - SEC Filing

* NABRIVA THERAPEUTICS PLC FILES FOR MIXED SHELF OF UPTO $225 MILLION - SEC FILING Source text (http://bit.ly/2HEW5CR) Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Nabriva Therapeutics ‍had $86.9 Mln In Cash, Cash Equivalents as Of Dec 31

* NABRIVA THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

Select another date: